Elicio Therapeutics reported that its Phase 2 AMPLIFY‑7P study of the KRAS‑targeted vaccine ELI‑002 7P achieved a 99% T‑cell response rate in 90 evaluable patients, with 85% of those patients showing simultaneous activation of both CD4 and CD8 T cells. 86% of the 630 mKRAS target antigens elicited measurable immune responses, and 88% of patients generated responses to their own tumor‑specific mutation. While the company highlighted broad reactivity across all seven KRAS epitopes, the specific figure of 67% was not independently confirmed in the available sources.
The preclinical data for the intratumoral candidate ELI‑004 showed complete tumor eradication in more than 90% of mouse models and conferred long‑term protection against recurrence. These results suggest that ELI‑004 could serve as an off‑the‑shelf immunotherapy for solid tumors when delivered directly into the tumor microenvironment, expanding the company’s therapeutic portfolio beyond the vaccine platform.
Elicio’s proprietary Amphiphile (AMP) platform is designed to deliver immunotherapeutics to lymph nodes, enhancing immune cell education and amplification. The robust immunogenicity observed in a diverse HLA population underscores the platform’s potential to generate broad, potent responses across a wide patient base, a key advantage for a KRAS‑mutant therapy that historically has been difficult to target.
The company will present the full immunogenicity data and preclinical results at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting on November 7‑8. Chief Medical Officer Christopher Haqq emphasized that the data “highlights the potential of ELI‑002 7P to benefit a broad population of patients with KRAS‑mutant pancreatic cancer.” Chief Scientific Officer Pete DeMuth noted that the ELI‑004 data “demonstrate[s] complete eradication of advanced solid tumors in > 90% of cases, followed by long‑term protection against recurrence.” CEO Robert Connelly added that the company remains “highly encouraged by the potential for our platform to provide a meaningful, broadly applicable, off‑the‑shelf therapeutic vaccine to treat common cancer types.”
Elicio’s financial position remains modest, with $22.1 million in cash and cash equivalents as of the end of Q2 2025 and a recent $10 million financing round. The company’s focus on advancing these clinical and preclinical milestones is intended to strengthen its pipeline and attract future investment, positioning it for potential growth once regulatory approvals are achieved.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.